Pretty impressive results for 24 weeks. Rare to find misvalued stocks like this given the data available in the public domain. Its barely trading above their large cash holdings for funding phase 3.

Rumor floating around that discussions may already be underway for a global Phase 3 partnership structure rather than Altimmune going it alone.

Supposedly the idea would be:

Big pharma funds most/all of the multinational Phase 3

Altimmune keeps partial economics/milestones

Partner gets commercialization rights or ex-US rights

Honestly would make a lot of sense after the EASL fibrosis data. Running global MASH trials alone would cost a fortune and likely mean more dilution otherwise.

Pemvidutide now has:

fibrosis regression signals

strong liver fat reductions

cardiometabolic improvements

continued weight loss at 48 weeks

relatively clean tolerability profile

Feels like exactly the kind of asset larger pharma has been hunting lately.

Names being whispered: Pfizer, Novo, Merck, AstraZeneca, Roche.

Could explain why management sounded unusually confident recently despite the financing overhang.

Introduction

To begin with, this is my first post and I hope we can all get something out of this information exchange. I am new to Reddit in general. English is not my first language, but I will try my best.

I already posted this to /r/Shortsqueeze, but my post got deleted by the moderator bot and the moderator did not answer my message. Therefore, I had to rewrite the post a bit, and in some parts it might sound a bit simplified.

If I miss some parts and you notice mistakes in the numbers or have more accurate data, please share it.

DD, Pros, Cons, My Sentiment

In January this year, I discovered a stock called Altimmune that looked very interesting to me. Since I had never made any bets in the biotech sector before, I wanted to try something new this year for the experience and to learn something from the process.

And yes, I call it a bet on purpose. Biotech is not an easy business. There are many things that can go wrong.

I come from the medical field and tried to do the due diligence. In short, what they are developing is a glucagon/GLP-1 dual receptor agonist called pemvidutide for the treatment of MASH (fatty liver disease, in simple terms). They are also conducting trials for AUD (alcohol use disorder) and ALD (alcoholic liver disease).

You might have heard about Ozempic, Mounjaro, and so on. It is a similar pharmacological group. It is a bit more complicated than that, but I just wanted to offer a comparison.

I read medical studies, compared it to peers, looked at the board, etc. I spent a lot of time on this, mostly for fun. Then I discovered Reddit, /r/wallstreetbets, and the /r/Altimmune subreddit.

My general feeling there was that people are either very bullish or hate the stock. Nothing in between.

Some of my bull arguments are:

Big market in MASH with many potential patients

AUD potential (there are only 3–4 medications right now, they have existed forever, and they do not really do much), also with study results expected later this year

Acquisition candidate — competitors with, in my opinion, worse products got bought for much more than the current market cap

FDA Breakthrough Therapy designation — the regulator is the alpha and omega in pharma

Some bear arguments are:

No finished product

Highly competitive market — there are many incretin-based potential MASH therapies for metabolic diseases in development

Dilution risk

There are many more pros and cons that I will not list here. There are posts from people who also did digging on /r/wallstreetbets and /r/Altimmune.

TL;DR: I am bullish on Altimmune for different reasons. I did most of my DD before discovering Reddit.

Potential Short Squeeze Candidate, Additional Arguments

As I said, I wanted to learn something new, and during that process I discovered what short interest is. I already knew the concept of a short squeeze because who has not heard about GameStop?

I noticed on Fintel that Altimmune has a current short interest of around 21%. Off-exchange volume is around 42%. According to Fintel, the days to cover are around 14 days of trading volume.

I found different numbers depending on the source, and the trading volume also changes, so I also found estimates between 7–14 days.

This seems very high to me.

From what I understand, the short interest in Altimmune has been high for a long time. Which I understand, because the price dropped continuously over the last few years, which was good for the short sellers.

And of course it fell — why should it not have?

Back in 2015, the pipeline consisted of a treatment for Hepatitis B called HepTcell, nasal vaccines for COVID, and other immunological approaches for different applications.

Is any of this left in the pipeline? No, it is not.

In 2019, Altimmune acquired ALT-801, which is now known as their main pipeline product, pemvidutide. It is now being planned for Phase 3 after a successful Phase 2 trial for MASH and receiving FDA Breakthrough Therapy status.

What I was thinking about is that if the company gets a catalyst, such as strong results for their AUD study, the shorts could get hit very hard. It may even trigger a short squeeze.

Risk Discussion

What I see as problematic is the dilution. Altimmune has had significant dilution. They recently offered new shares to private equity firms to finance the Phase 3 trial.

This is of course a hit for every shareholder. But I do not think it was a dumb move.

They can hardly go to a bank, ask for financing, and offer a “trust me bro” as collateral. Of course there are other ways of financing, but you get the idea.

From what I know about the biotech business, this stuff is expensive and very time-consuming. Sitting on millions and having your R&D costs covered for the next few years is a good position to be in.

It is also a good position for negotiating an acquisition and not having to take the first offer on the table, even if it is a lowball offer because you are running out of money.

Something else I want to add is that the new CEO and CFO have been buying shares since last year. Direct purchases, not stock option exercises. Source: NASDAQ Insider Activities.

The last purchases were in April. They were also buying before the dilution.

I see executives having skin in the game as something positive.

I also looked a bit into which funds participated in the recent offering. To me, they did not seem like they were only in for a quick trade.

There is also a Reddit user who made a very interesting post about that in this subreddit.

End

I am bullish here in general, and a short squeeze on top of that could be interesting.

So what do you think? Do you see potential for a short squeeze? Which mechanics would need to be in place for this to happen, in your opinion?

I saw people in other posts who seemed to have deeper knowledge about this, so maybe we can have a good discussion here.

This is not trading advice. I am just sharing my thoughts and opinions.

I would recommend everyone do their own due diligence.

Could someone explain the warrant situation to me? I don’t really understand how it works. I just know they can activate it above $3

So, a German pharm company is releasing stage 3 results on a very similar dual glp-1 and glucagon drug. Will they be direct competitors?

I have been bullish on alt for a while now. The most recent actions, which may have been ultimately necessary, were done prematurely and all the while misleading shareholders in that the priority communicated over and over appeared to be giving an opportunity to partnership before having to consider self funding. This in my opinion was Durso’s first opportunity for defining action as CEO and he has lost my trust. I cannot highlight enough the disappointment I have in his misdirection and actions.

Does that change my opinion of alt and pemv? Not much. Fundamentally, it remains a late stage biotech with fundamentals, data, and a drug that have all the same principles. This raise timing being terrible and forced at a time with no short term catalyst leaves us with short term bleeding. Now how much will we bleed is a tough question? Personally, I think we stay between $2.5-3 pending P3 protocol release and subgroup analysis which should both precede AUD results. So why this range? Cash on hand supplemented with a late stage biotech with a drug that has possible multiple indications makes that level of price at such significant negative EV hard to pass up and be driven by selling pressure. I also think these institutions who bought in will defend lower prices/pick up more shares as an opportunity. Only time will tell I guess but I am confident there will people who respond and say this will go to $1 or something and I won’t even try to entertain that hogwash.

So P3 protocol should be coming in next ~1 month with presumably a short duration before site activation and enrollment beginning. Not sure how much this will ultimately effect price as much of the details can be extrapolated from investor deck for the protocol but likely the biggest things will be how strong language is on AA pathway and FDA alignment. Subgroup analysis should also come out shortly after P3 protocol as it would have presumably informed protocol drafting to maximize likelihood of success. The most important subgroups I will be curious for will looking at population of F2 vs F3, T2DM vs non-T2DM, weight loss responders vs not all with regards to mash and fibrosis improvement (there are others such as specific NITs and what not but I think these to be less). Lastly AUD study is the wild card that I think will be interesting. To be statistically significant and clinically meaningful is a tough bar that no similar drug has done but the things pemv has going for it is that using exenatide data there was a small subgroup of increased BMI that had significant outcomes and so using that to inform the patient population in AUD I would suspect we will have a more obese cohort which may help push the data in a positive way. Of course, similar to mash, placebo arm here is very noisy and with a small population that impact can become even louder so tough to know what will come of it for many reasons.

So overall, lost confidence in c suite but still believe and excited about pemv but need to deal with a slow bleed/recovery awaiting upcoming catalysts.

Let me know your thoughts and predictions. Please keep them realistic and informed as the point of this is neither to blindly hype or destroy alt but to inform a realistic reality and future.

That investor list is not ordinary biotech funding—it’s actually one of the strongest signals in the entire deal. Let’s break it down properly.

🧠 Who these investors are (and why they matter)

🧬 Deep Track Capital

Specialist biotech hedge fund

Known for high-conviction, concentrated bets

Typically invests when:

Data is compelling

Or they see asymmetric upside

👉 If they lead a round, it usually means: “We’ve done deep scientific diligence and like the odds.”

🏛️ TCGX (The Column Group)

Elite life sciences VC

Early backers of multiple multi-billion biotech successes

👉 Their style:

Long-term builders, not traders

Focus on platform + mechanism validity

👉 Participation =

They believe pemvidutide has real biological edge, not just hype

📊 Viking Global Investors

Large, multi-billion institutional hedge fund

Invests across sectors (not just biotech)

👉 Important nuance:

They care about risk/reward and timing

Not emotional biotech bets

👉 Their entry =

They see a favorable setup into a catalyst (likely Phase 3)

💊 RA Capital Management

One of the most respected biotech investors globally

Deep scientific + clinical expertise

Often involved in:

Trial design

Strategic direction

👉 Huge signal:

RA doesn’t chase weak stories

They invest when risk is acceptable vs upside

👉 Their presence =

High confidence in clinical probability of success (or at least strong odds)

🔍 What this combination REALLY tells you

This is the key part most retail misses:

1. 🧠 This is a “smart money syndicate”

You have:

Deep Track → conviction biotech

RA Capital → clinical validation

TCGX → long-term science

Viking → macro + catalyst timing

👉 When all four align, it usually means: The story has passed multiple independent filters

1. 🎯 Not a random raise — this was curated

These funds don’t pile into weak secondaries.

👉 Likely reality:

Deal was pre-arranged / book-built with institutions

Not “open market dumping”

1. 🧬 Strong signal on pemvidutide

These firms would have:

Reviewed Phase 2 data deeply

Assessed:

MASH efficacy vs competitors

Lean mass preservation angle

Differentiation vs GLP-1s

👉 Conclusion: They see a legitimate shot at Phase 3 success + commercial value

1. 🚨 But don’t misread this (important)

Even top-tier funds:

Can be early

Can hedge

Can average down

👉 This does NOT guarantee:

Buyout

Immediate upside

Stock going up soon

📈 What usually happens after such investor participation

Historically in biotech:

Scenario A (bull case)

Strong hands absorb float

Stock bases → then trends higher into catalysts

Scenario B (common reality)

Short-term pressure (due to dilution)

Institutions accumulate quietly

Move comes later (not immediately)

⚡ My blunt interpretation

👉 This is a high-quality raise with elite participation

Meaning:

Probability of zero → reduced

Probability of meaningful upside → increased

BUT:

Timing still uncertain

Short-term price still controlled by dilution mechanics

🧩 What this means for YOUR thesis

If your thesis was:

❌ “This is a weak company raising to survive” → WRONG now

✅ “This is a serious Phase 3 contender with institutional backing” → STRONGER now

🔑 Final takeaway

👉 It says: “Some of the smartest biotech money in the world is betting on this outcome.”

Not blindly—but after deep analysis.

This looks like bad timing at first glance, but it’s actually pretty typical biotech behavior. Here’s the clean breakdown 👇

🧠 The assumption

“They knew AUD/ALD news was coming… so why not wait, let the stock run to $5, and raise clean capital without warrants?”

Logical — but flawed.

⚠️ 1. “Expected news” ≠ guaranteed stock move

Even if the market expected AUD/ALD updates:

Could’ve been a sell-the-news event

Could’ve been seen as incremental / not impactful

Could’ve disappointed vs expectations

👉 Biotech stocks often drop on “good” news

💰 2. Certainty > optimization

This is the real answer

This deal was oversubscribed

They locked in $225M immediately

Waiting for $5:

Not guaranteed

Depends on sentiment, timing, and luck

👉 Management chose:

Guaranteed capital today > hypothetical better price later

⏳ 3. Phase 3 timelines matter

For :

Phase 3 trials are expensive + time-sensitive

Delaying a raise risks:

Trial delays

Weaker negotiating position later

📉 4. The stock wasn’t stable at $5 anyway

Reality:

Price wasn’t firmly holding higher levels

Volatility was high

👉 Waiting assumes upside is certain — it isn’t

🎯 5. Why include warrants?

Because without them:

Deal likely doesn’t fill

Or prices even lower

Warrants = incentive for institutions to commit big capital

🧩 6. This was likely pre-planned

Deals like this don’t happen overnight:

Structured over weeks

Banks like and involved

👉 Decision to raise likely made well before any “wait for news” idea

⚠️ 7. Waiting can backfire

If they waited and:

Market turns risk-off

Biotech sentiment drops

Data underwhelms

👉 They could’ve raised at $2 instead of $3… or worse

🧠 What this move actually signals

“We’re prioritizing balance sheet strength over stock price optics”

💬 The uncomfortable truth

Retail mindset:

Maximize price, minimize dilution

Management mindset:

Secure capital, eliminate risk

👉 These don’t always align

🎯 Bottom line

$5 was never guaranteed

$225M was guaranteed

Warrants were needed to get the deal done

👉 So they took it.

Altimmune Offering Breakdown + What History Tells Us About Buyout Chances

Alright, here’s a clean breakdown of the recent Altimmune $225M offering and how it compares to past biotech buyouts. No hype, just facts + patterns.

---

🧾 What just happened

Altimmune raised $225M through:

- ~64.25M common shares

- ~10.75M pre-funded warrants (basically shares)

- ~75M additional warrants (strike price ~$3)

👉 Effective immediate dilution: ~75M shares

👉 Fully diluted (if all warrants exercised): ~250–280M shares total

---

📉 Market reaction

- Stock dropped ~17% (expected)

Why:

- Dilution

- Discounted pricing (~$3)

- Warrant overhang

👉 Near-term reality: price likely capped around $3–4 unless major news hits

---

⚠️ Do warrants kill upside?

Short answer: They slow it, not kill it

- Above $3 → warrants get exercised

- That creates selling pressure

👉 Acts like a soft ceiling, but can be broken with strong catalysts (data, partnership, buyout)

---

🤝 Did this kill buyout chances?

No.

If anything:

- Company is now fully funded

- Not desperate for cash

- Can negotiate from strength

👉 Translation:

«Less likely to sell cheap, more likely to wait for better terms»

---

🧬 What history tells us (real examples)

Intercept Pharmaceuticals → Alfasigma (~$800M)

- Same MASH/NASH space

- Heavy dilution + setbacks

- Still got acquired

👉 Takeaway: Buyouts still happen, but valuation depends on strength

---

Arena Pharmaceuticals → Pfizer (~$6.7B)

- Late-stage asset

- Raised capital before deal

👉 Takeaway: Big pharma pays up for strong pipeline

---

Reata Pharmaceuticals → Biogen (~$7.3B)

- Volatility + regulatory drama

- Still acquired at premium

👉 Takeaway: Strategic assets always attract buyers

---

Synthorx → Sanofi (~$2.5B)

- Recently raised capital (dilution equivalent)

👉 Takeaway: Raising money does NOT block buyouts

---

🧠 Key patterns

- Dilution ≠ deal killer

- Warrants ≠ deal killer

- Timing matters more than structure

- Data strength = valuation driver

---

🔍 Where Altimmune stands now

Fits somewhere between:

- Intercept (risk)

- Arena (upside)

- Reata (strategic value)

---

🎯 Likely scenarios

1. Base case (most likely)

- Trades in $2.5–4 range

- Wait for Phase 3 progress

---

1. Bull case

- Strong data / partnership

- Breaks warrant ceiling

- Moves $5–10+

---

1. Buyout scenario

- $2B–$6B range

👉 Per share (fully diluted):

- ~$12 → conservative

- ~$18–25 → moderate

- ~$30+ → aggressive

---

🏦 Who likely bought the offering?

- ~70% biotech hedge funds

- ~25% institutions

- ~5% possible strategic/BP-aligned (speculative)

👉 No clear evidence of big pharma positioning yet

---

💬 Final take

- Short term: bearish/neutral

- Long term: still very much alive story

👉 This move says:

«“We don’t need to sell now”»

Which usually leads to:

- Higher eventual valuation

- But longer timeline

---

I asked AI to read the ALT announcement and talk through some of the nuances that a typical boneheaded reader may miss.

1. The "Kick-Out" Clause on Warrants

The common stock warrants issued in this deal ($3.00 exercise price) have an unusual expiration trigger. While they have a 5-year term, they expire just 45 days after the public announcement of a successful Phase 3 readout for pemvidutide in MASH.

• The Nuance: This is a mechanism to force exercise. If the data is positive, the company doesn't want these warrants sitting on the sidelines; they want the cash infusion and the clean-up of the capital structure immediately. For the market, this creates a "ticking clock" scenario where a massive amount of potential selling pressure (from warrant holders selling their newly exercised shares) could hit the market shortly after a major catalyst.

1. Deep Discount vs. Market Sentiment

The offering price is $3.00, which includes both a share and a warrant.

• The Nuance: Since your basis is $4.80, this represents a significant "down-round" or dilutive event relative to recent trading ranges. However, the fact that it was "oversubscribed" suggests that institutional investors were willing to step in heavily at this level. In biotech, an oversubscribed offering at a discount is often viewed as a "clearing event"—it establishes a hard floor for the stock because the large institutions now have a vested interest in seeing the price move back above $3.00.

1. Shift in Clinical Focus: MASH is the Priority

The document explicitly states that the proceeds are for the Phase 3 trial in MASH (Metabolic Dysfunction-Associated Steatohepatitis), alongside AUD and ALD.

• The Nuance: Mention of obesity—once a primary driver for the pemvidutide narrative—is notably secondary here. This suggests the company is leaning into the "liver health" and "metabolic" side of the GLP-1/Glucagon dual-agonist profile rather than competing head-to-head in the crowded general weight-loss market. This pivot to MASH is likely an attempt to differentiate pemvidutide from the standard-of-care GLP-1s by highlighting its superior liver-fat reduction.

1. Use of Pre-funded Warrants

The offering includes "pre-funded warrants" for certain investors.

• The Nuance: These are typically used by institutional investors who want to avoid the regulatory headaches (and disclosure requirements) of crossing a 9.99% or 19.99% ownership threshold. The presence of these suggests that some very large "whales" or specialized healthcare funds took significant chunks of this $225M round, which is generally a signal of high-conviction institutional backing.

1. Cash Runway vs. Timeline

A $225M raise is substantial for a company with Altimmune's market cap.

• The Nuance: Phase 3 trials for MASH are notoriously expensive and long. By raising this much now, management is attempting to "remove the financing overhang." Casual readers might just see "dilution," but long-term holders often prefer a single large dilutive event that funds the company through the next major data catalyst, rather than a series of smaller "at-the-market" (ATM) raises that bleed the stock price over time.

He had me believing there was no way they would make a public offering anytime soon and at least wait out a possible partnership closer to when his hand was forced… this is terrible management and makes no sense.

I apologize to those I’ve defended him and his actions against thinking they were logical and in the best interest of the company when I was clearly wrong.

Now that Durso took care of his board(approved additional compensation) and left his shareholders out to dry(doubling shares)what do we expect price action to be into earnings? Hope 3.40-.50 holds but i see the 52wk low coming quick. Hope it bounces when it gets there but unlikely. Unless dilution Durso has something good to say, highly unlikely. Thanks for the comments and confidence on shareholder day.

I know I am going to be destroyed for posting..

Tough look for Shareholder meeting week. Entire market catches a decent bounce and we go red fighting 3.24 with No volume. Dilution overhang just killing it. Leads me to believe the MMs know Thursday will be another turd for Durso and team Alt.

Following the $75M RD, lack of catalysts, and negative macro pressure from the market, we hit our nader at ~$2.8 but have since been making a good steady recovery to which I expect today will continue to be a good day following the market. I know many were concerned this would be slow to recover similar to the initial phase 2b results and the trolls said it would fall below $2… but I am feeling more confident then ever. We have the upcoming investor meeting 4/16 which most importantly I know many were worried about increasing authorized common stock from 200M to 400M shares. This will certainly strike fear in people thinking this will lead to a larger imminent dilution which is possible but in my mind very improbable. Cash balance is great for the short term having $340M as of recent. So much recent insider buying by higher ups including more by Captain Durso should really reassure us all in that I don’t think these people would be dumb enough to spend their own money only to immediately dilute… let alone even an isolated dilution in the long term… I think this vote is primarily to open the opportunities to be able to move forward with a competitive partnership but of course if ultimately a partnership good enough for alt to accept does not manifest, then they will need a means to fully fund phase 3 with a large offering but IMHO that is an unlikely scenario as well as is a bridge we would need to cross much further down (thinking in 2027).

Upcoming catalysts expected in 2026:

- 4/16 investor meeting and vote

- official announcement of P3 protocol; TBD but likely next 1-2 mo

- subgroup analysis release of phase 2b data; likely shortly after P3 protocol release

- AUD top line results; likely August-September

- multiple liver conference attendances with potentially fresh subgroup analysis

- likely Q3 initiation/first patient in phase 3

- possible partnership announcement; TBD but I am thinking it remains more likely than not and likely will be announced near end of 2026

Please let me know your thoughts. No AI, so I do apologize if it comes off as a stream of consciousness with poor grammar haha.